相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial
A. O. Stirban et al.
DIABETES OBESITY & METABOLISM (2016)
Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs-A mechanistic revisit to understand their mode of action
Prachi Gupta et al.
PHARMACOLOGICAL RESEARCH (2016)
Diabetes Dyslipidemia
Jonathan D. Schofield et al.
DIABETES THERAPY (2016)
Diabetes Dyslipidemia
Jonathan D. Schofield et al.
DIABETES THERAPY (2016)
Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes
Sanjay Chatterjee et al.
SCIENTIFIC REPORTS (2015)
Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus A Global Case-Control Study in 13 Countries
Frank M. Sacks et al.
CIRCULATION (2014)
Minireview: Challenges and Opportunities in Development of PPAR Agonists
Matthew B. Wright et al.
MOLECULAR ENDOCRINOLOGY (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Metabolic effects of muraglitazar in type 2 diabetic subjects
M. Fernandez et al.
DIABETES OBESITY & METABOLISM (2011)
Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study
R. M. Anjana et al.
DIABETOLOGIA (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
LANCET (2010)
Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention
Kiran Musunuru
LIPIDS (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets
Fanny Lalloyer et al.
DIABETES (2006)
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy
DM Kendall et al.
DIABETES CARE (2006)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo
FL Egerod et al.
BIOMARKERS (2005)
Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: A summary of the evidence for the US Preventive Services Task Force
EP Whitlock et al.
ANNALS OF INTERNAL MEDICINE (2004)
Role of peroxisome proliferator -: Activated receptor-γ in the glucose-sensing apparatus of liver and β-cells
H Kim et al.
DIABETES (2004)
Use and abuse of HOMA modeling
TM Wallace et al.
DIABETES CARE (2004)
Pathophysiology of type 2 diabetes
AJ Scheen
ACTA CLINICA BELGICA (2003)
Evaluation of insulin sensitivity in clinical practice and in research settings
LU Monzillo et al.
NUTRITION REVIEWS (2003)
Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects
M Hawkins et al.
DIABETES (2002)
分享论文
